Article Details
Retrieved on: 2018-01-07 20:56:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>... optimal efficacy and reduced toxicity. Teneobio plans to file its first IND on its lead program, TNB-383B (anti-BCMAxCD3) for the treatment of multiple myeloma in Q4 of 2018. The company has received funding from institutional investors, including <b>Lightspeed Venture Partners</b> and Sutter Hill Ventures.</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here